Cargando…
SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179491/ https://www.ncbi.nlm.nih.gov/pubmed/32335097 http://dx.doi.org/10.1016/j.diabres.2020.108162 |